List of Services

DKMS Life Science Lab gGmbH St. Petersburger Str. 2, 01069 Dresden Tel. (0351) 89993-000

> Fax: (0351) 89993-001 Email: info@dkms-lab.de

Opening hours for receipt of materials on the following working days:

Mon - Fri

08.00 a.m. - 4.00 p.m.

MANDATORY

Please communicate with us before sending samples for the first time.

ID: **6708**, Version: **004/12.2024** Valid from: **03.12.2024** Next review: **03.12.2026**

List of Services

Contents

| 1 | Abr | ore | viation | 3 |
|---|------|-----|--|----|
| • | 1.1 | | ethods | |
| | 1.2 | | eneral abbreviations | |
| 2 | | | nissioning, material extraction, pre-analytics, communication of results | |
| | 2.1 | | ample material | |
| | 2.1. | | Blood | |
| | 2.1. | .2 | Swabs | 5 |
| | | | Other | |
| | 2.2 | | aterials for sample collection/sample transport | |
| | 2.3 | | ample labelling | |
| | 2.4 | | esting request/requisition | |
| | 2.5 | | pecial features for genetic analyses (German Genetic Diagnostics Act) | |
| | 2.6 | - | ollection of the test material | |
| | 2.6. | | General | |
| | 2.6. | | Serum | |
| | 2.6. | | Whole blood with no additives (neutral tube) | |
| | 2.6. | | Acid citrate dextrose blood (ACD) | |
| | 2.6. | | Citrated blood | |
| | 2.6. | .6 | Citrate phosphate dextrose adenine blood (CPDA) | 9 |
| | 2.6. | .7 | EDTA blood | |
| | 2.6. | .8 | Heparin blood | |
| | 2.6. | .9 | Plasma (citrate plasma, EDTA plasma, heparin plasma) | 9 |
| | 2.6 | .10 | Swabs: Patient or donor swab | |
| | 2.6 | .11 | Materials not listed | 10 |
| | 2.7 | Co | ommunication of results or findings | 10 |
| | 2.8 | | omplaints | |
| 3 | Alp | hal | betical list of services | 11 |
| 4 | Suk | ose | equent reporting from laboratory testing | 14 |
| | | | | |

| ID: 6708 , Version: 004/12.2024 Valid from: 03.12.2024 Next review: 03.12.2026 |
|--|
|--|

List of Services

1 Abbreviation

1.1 Methods

| ELISA | Enzyme-linked immunosorbent assay | |
|---|---|--|
| LCT Complement-dependent (micro)lymphocytotoxicity test | | |
| LCT+DTT Complement-dependent (micro) lymphocytotoxicity test using DTT for inactivation of the IgM antibodies | | |
| NGS-E | -E Next generation sequencing of typing-relevant exons using short PCR amplicons (<1kb) | |
| NGS-LR | NGS-LR Next generation sequencing of long-range PCR amplicons (>1kb) | |
| PCR Polymerase chain reaction | | |
| SSO | Sequence-specific oligonucleotide | |
| XMAP-M | Antibody detection/screening by means of bead array technology (Luminex, antigen mix) | |
| XMAP-SA Antibody specification by means of bead array technology (Luminex technology, single antigen) | | |

1.2 General abbreviations

| μg | Microgram | |
|--------|---|--|
| μl | Microlitre | |
| ACD | Acid citrate dextrose | |
| AB | Antibodies | |
| CE-IVD | In vitro diagnostic products with CE marking in compliance with EU standards | |
| CPDA | Citrate phosphate dextrose adenine | |
| DTT | Dithiothreitol | |
| EDTA | Ethylenediaminetetraacetic acid or its salts | |
| g | Gram | |
| GenDG | Genetic Diagnostics Act – a German law concerning the genetic testing of humans | |
| HD | High throughput laboratory | |
| HLA | Human leukocyte antigens | |
| KL | Clinical laboratory | |
| mg | Milligram | |
| min. | Minimum | |
| Min. | Minute | |
| ml | Millilitre | |
| mm | Millimetre | |
| ng | Nanogram | |
| TAT | Turnaround time (processing time for a sample in working days from the beginning of the workflow); | |
| | individual agreements can be made with a contract | |
| Unorm | Units normalised to a protein content of 1 mg/ml | |
| WD | Working days | |
| | (high throughput area: 20 working days (Mon-Fri) corresponding to 28 calendar days as the standard TAT) | |

| D: 6708 , Version: 004/12.2024 | Valid from: 03.12.2024 | Next review: 03.12.2026 |
|--|-------------------------------|--------------------------------|
|--|-------------------------------|--------------------------------|

List of Services

2 Commissioning, material extraction, pre-analytics, communication of results

2.1 Sample material

2.1.1 Blood

The alphabetical list of services shows the test materials needed for the analyses you require. You can freely select from the sample containers listed below.

Several samples of the same type should be sent in if they need to meet a very exacting scope of analysis, if you are requesting analyses with high material requirements or if the pre-analytics differs in the case of identical material. Therefore, if applicable, please note the pre-analytical information for the individual analyses.

| Sequence | Material | Monovettes | Vacuettes | Application | Storage temperature | |
|----------|----------------------------|--------------|--|-------------------------------------|---------------------|--|
| Sequence | | (cap colour) | (cap colour) | Application | when shipping | |
| 1 | Serum | Serum gel | Serum | e.g. serology, | uncooled * | |
| ' | Serum | (brown) | (red) | immunology | uncooled | |
| 2 | Whole blood | Neutral tube | Neutral tube (white) Immunohaematology | lmm un ab a matala au | unacalad * | |
| 2 | with no additives | (white) | | uncooled * | | |
| | | | | e.g. | | |
| 3 | EDTA blood (preferably) | EDTA (red) | EDTA (purple) | immunohaematology, | uncooled * | |
| | | | | blood type analytics, DNA analyses | | |
| 4 | Citrated blood | Citrate | Citrate (blue) | e.g. DNA analyses | uncooled * | |
| | | (green) | \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ | | | |
| 5 | Heparin blood | Li-heparin | Li-heparin | e.g. DNA analyses | uncooled * | |
| | | (orange) | (green) | | | |
| 6 | ACD blood | _ | ACD-B | e.g. blood type analytics, | uncooled * | |
| | 7 CD Blood | | (yellow) | DNA analyses | anocoloa | |
| 7 | CPDA blood | CPDA | CPDA (yellow) | e.g. blood type analytics, uncooled | | |
| | Of DA blood | (yellow) | Or DA (yellow) | DNA analyses | uncoolea | |

^{*} The test material is stored or shipped uncooled. Extreme cold (<0°C), or heat (>40°C) should be avoided.

|--|

List of Services

2.1.2 Swabs

| Sample container | Description | Application | Storage |
|-----------------------|--------------------------------|--------------------------|-------------|
| | | | temperature |
| Donor swab | Swab without transport medium, | DNA analyses and/or | |
| (swab) | in transport envelope | CMV status determination | |
| | | for potential stem cell | uncooled * |
| | | donors or study | |
| | | participants | |
| Patient or donor swab | Swab without transport medium, | DNA analyses | uncooled * |
| (swab) | in transport envelope | | uncooled |

^{*} The test material is stored or shipped uncooled. Extreme cold (<0°C), or heat (>40°C) should be avoided.

2.1.3 Other

| Sample container | Description | Application | Storage | |
|----------------------|--|---------------|-------------|--|
| | | | temperature | |
| Reaction tube 1.5 ml | With safety cap | Extracted DNA | uncooled * | |
| Reaction tube 2 ml | With safety cap | Extracted DNA | uncooled * | |
| 96-well microplates | Preferably: 330 µl, 96 round wells, V- | Extracted DNA | uncooled * | |
| | bottom plate, polypropylene | | uncooled | |

^{*} The test material is stored or shipped uncooled. Extreme cold (<0°C), or heat (>40°C) should be avoided.

2.2 Materials for sample collection/sample transport

After consulting with the laboratory, the materials can be provided for sample collection or sample transport for swabs or DNA samples. Order forms can be sent in along with test specimens via a courier service. Any changes to sample materials, the introduction of new methods or changes to evaluation criteria must be notified in good time.


2.3 Sample labelling

Each sample container must be clearly labelled. When it is necessary for particular analyses, the corresponding order must also be labelled with an identical and unique sample barcode. Certain requirements apply in these cases, and these are provided in advance as a basis of the contract and are discussed with the customer.

| D: 6708 , Version: 004/12.2024 | Valid from: 03.12.2024 | Next review: 03.12.2026 |
|--|-------------------------------|--------------------------------|
|--|-------------------------------|--------------------------------|

List of Services

The following guidelines apply for the sample barcode:



2.4 Testing request/requisition

Where required according on the type of analysis, each sample must have an accurately completed laboratory order attached. This applies equally to both paper-based and electronic orders. The following patient-specific information is required for clinical investigations:

| Mandatory | | Necessary for correct diagnosis and plausibility check | |
|-----------|--|--|----------------------------------|
| • | Surname, first name, date of birth (gender optional) or unique identifier (e.g. barcode/GRID of donor) | • | Clinical diagnosis or symptoms |
| • | Depending on the order (e.g. privately insured), address of the patient | • | Information on previous findings |
| • | Test materials with date of sample collection. | • | Medication, if applicable |
| • | Scope of testing requested | | |
| • | Sender (plus ward or department in the case of hospitals) with doctor's signature | | |

| ID: 6708 , Version: 004/12.2024 | Valid from: 03.12.2024 | Next review: 03.12.2026 |
|---|-------------------------------|--------------------------------|
|---|-------------------------------|--------------------------------|

List of Services

For samples in the high throughput area, the following information is required:

| Mandatory | Optional | | | |
|---|--|--|--|--|
| Unique barcode | Requisition with barcode in paper form accompanying the sample | | | |
| Scope of testing requested | | | | |
| Sender | | | | |
| List with number of samples and identifiers in digital form | | | | |

Samples that cannot be uniquely identified, e.g. if labelling is missing or unclear or there is no barcode, can only be processed if the sender creates a clear assignment before further processing. To this end, written confirmation is obtained from the person responsible for the identification and documented.

For studies or anonymous donor typing, separate arrangements are agreed with the sender and put into writing.

2.5 Special features for genetic analyses (German Genetic Diagnostics Act)

- The Genetic Diagnostics Act has been in effect since 01/02/2010 and concerns testing that is directed at inherited or prenatally acquired characteristics of human genetic material (chromosomes, DNA, genes). The law also applies to gene products if the testing is directed at the genetic make-up.
- In the case of genetic testing for medical purposes (diagnostic or predictively with disease association), it is absolutely imperative that the patient is informed and provides a signed declaration of consent. This must contain the subject and scope of the testing, the consent to the sample collection and to the testing, and to the findings being noted or being destroyed as well as the decision regarding retention of the sample following the analysis. Prior to the declaration of consent, the nature, scope and implications of the testing must be clarified and documented. In the case of persons who are not able to consent (children or those under supervision), the signature of the legal representative must be obtained.
- If there is no declaration of consent, the laboratory must not begin the aforementioned analyses.
- Otherwise, the provisions of the current version of the German Genetic Diagnostics Act apply.

| ID: 6708 , Version: 004/12.2024 | Valid from: 03.12.2024 | Next review: 03.12.2026 |
|---|-------------------------------|--------------------------------|
|---|-------------------------------|--------------------------------|

List of Services

2.6 Collection of the test material

2.6.1 General

- Please inform the test subjects of any particular preparatory measures that they need to observe
 for the sample collection or beforehand (e.g. avoid eating food or taking medicines, and
 suchlike).
- Please use the prescribed sample containers and tag or label them during the sample collection.
 It may be helpful to show the test subject the filled tubes bearing their name.
- If several samples are collected for one requisition, they must be labelled individually.
- In general, medication should not be taken until after blood sample collection.
- Samples should never be exposed to direct sunlight.
- Contaminated materials should be disposed of properly.
- Avoid injuries by using appropriate materials (safety cannulas, safety lancets, sharps containers).

2.6.2 Serum

- Serum is the fluid portion of the blood after the process of blood clotting is completed.
- After taking a sample, leave the blood <u>standing</u> in the serum tube to clot for at least 20 minutes.
- Centrifuge it beforehand if necessary (approx. 10 minutes at approx. 3000 rpm). Then transfer
 the supernatant (the serum) into aliquot containers intended for this purpose and label it as
 serum.
- Store the material in accordance with the instructions for the test parameter in question.

2.6.3 Whole blood with no additives (neutral tube)

• Whole blood with no Coagulation additives. Invert the neutral tube carefully several times and store in accordance with the instructions for the test parameter in question.

2.6.4 Acid citrate dextrose blood (ACD)

- Fill the ACD tube to the fill line.
- Invert the filled tube carefully several times and store in accordance with the instructions for the
 test parameter in question. If you forget to invert it, the ACD and the blood will not be sufficiently
 mixed, and this will result in blood clot formation. This means that determinations may be
 distorted or rendered impossible.

|--|

List of Services

2.6.5 Citrated blood

- Fill the citrate tube to the fill line.
- Invert the filled tube carefully several times and store in accordance with the instructions for the
 test parameter in question. If you forget to invert it, the citrate and the blood will not be sufficiently
 mixed, and this will result in blood clot formation. This means that determinations may be
 distorted or rendered impossible.

2.6.6 Citrate phosphate dextrose adenine blood (CPDA)

- Fill the CPDA tube to the fill line.
- Invert the filled tube carefully several times and store in accordance with the instructions for the
 test parameter in question. If you forget to invert it, the CPDA and the blood will not be sufficiently
 mixed, and this will result in blood clot formation. This means that determinations may be
 distorted or rendered impossible.

2.6.7 EDTA blood

- Fill the EDTA tube to the fill line.
- Invert the filled tube carefully several times and store in accordance with the instructions for the
 test parameter in question. If you forget to invert it, the EDTA and the blood will not be sufficiently
 mixed, and this will result in blood clot formation. This means that determinations may be
 distorted or rendered impossible.

2.6.8 Heparin blood

- Fill the Li-heparin tube to the fill line.
- Invert the filled tube carefully several times and store in accordance with the instructions for the
 test parameter in question. If you forget to invert it, the heparin and the blood will not be
 sufficiently mixed, and this will result in blood clot formation. This means that determinations
 may be distorted or rendered impossible.

2.6.9 Plasma (citrate plasma, EDTA plasma, heparin plasma)

- Plasma is the fluid portion of the blood before the onset of blood clotting.
- Draw the blood into the relevant sample tubes (citrate, EDTA or heparin tubes).
- Carefully invert and centrifuge immediately (approx. 10 minutes at 3000 rpm)
- Withdraw the supernatant (the plasma) and transfer it into sample tubes intended for this purpose. Label the tube with the type of plasma.
- Store the material in accordance with the instructions for the test parameter in question (e.g. deep-frozen, protected from light).

| ID: 6708 , Version: 004/12.2024 | Valid from: 03.12.2024 | Next review: 03.12.2026 |
|---|-------------------------------|--------------------------------|
|---|-------------------------------|--------------------------------|

List of Services

2.6.10 Swabs: Patient or donor swab

- Open the swab packaging and remove the swab. Make sure not to touch the head of the swab with your fingers. Use each swab only once.
- Please take a swab with each of the enclosed swabs.
- To do this, wipe the inside of the cheeks using pressure for at least 60 seconds (including the folds at the upper and lower jaws). Move high and low as well as rotating to collect sufficient cells from the buccal mucosa. (Saliva by itself is insufficient!)
- Please let used swabs dry for two minutes and then put them in the cardboard envelope without the plastic cover.

2.6.11 Materials not listed

• Consultation in writing requested via Typing@dkms-lab.de.

2.7 Communication of results or findings

Results or findings are generally communicated electronically via an agreed delivery channel, by secure email, by post or during a consultation in person. The contact person for receiving communications regarding the results or findings will be specified in the contract.

The appropriateness of all examination procedures used is ensured and demonstrated by

- verification or validation of the procedures,
- use of recognized and up-to-date procedures and regular review of their timeliness,
- examination of the certificate of requirement, if available for examination.

Nevertheless, a minimal residual risk that influences the reporting of results and findings cannot be completely ruled out, cannot be completely ruled out. In such cases, the user will be informed informed immediately. Detailed information on the procedures used can be found at Typing@dkms-lab.de.

2.8 Complaints

Any complaints received are recorded and handled by complaint management. In order to identify any systematic problems and introduce improvements, they are classified and analysed regularly. Contact:

Typing@dkms-lab.de / Clinical laboratory and search unit: searchunit_dd@dkms-lab.de

|--|

List of Services

3 Alphabetical list of services

| Item | Test (DAkkS accredited according to DIN EN ISO 15189 in its currently valid version) | Material/quantity | Evaluation criteria | Method | Application area | TAT (in WD) |
|------|---|--|---|----------------|---|----------------|
| 1 | HLA Antibodies HLA class I and II | Serum 1 ml | Negative/ positive | XMAP-M | KL with CE-IVD-certified | as per |
| 2 | complement-independent | Whole blood 10 ml | see findings | XMAP-SA | reagents | |
| 3 | CMV virus antibodies (IgG) | Swab 2 units | negative: < 8 unorm borderline: 8 - 20 unorm positive: > 20 unorm | ELISA | HD with commercial kit | 20 |
| 4 | HLA base profile | Swab 2 units | | | | |
| 5 | exon | EDTA blood** 2 ml | | | | |
| 6 | HLA class I (HLA-A*; HLA-B*; HLA-C*) and HLA class II (HLA-DRB1*; HLA-DQB1*; HLA-DPB1*; HLA-DRB3/4/5*; HLA-DQA1*; HLA-DPA1*) Optional additional profile (ABO*, RhD*, CCR5Δ32*) | Extracted DNA: Volume: > 100 μl DNA concentration: minimum 20 ng/μl | see findings | NGS-E | HD with reagents developed in-house | 20 |
| 7 | HLA base profile + CMV exon HLA class I (HLA-A*; HLA-B*; HLA-C*) and HLA class II (HLA-DRB1*; HLA-DQB1*; HLA-DPB1*; HLA-DRB3/4/5*; HLA-DQA1*; HLA-DPA1*) CMV virus antibodies (IgG) Optional additional profile (ABO*, RhD*, CCR5Δ32*) | Swab 3 units | see findings | NGS-E ELISA | HD with reagents developed in-house with commercial kit | 20 |

|--|

List of Services

| Item | Test (DAkkS accredited according to DIN EN ISO 15189 in its currently valid version) | Material/quantity | Evaluation criteria | Method | Application area | TAT (in WD) |
|----------------|--|--|---------------------|--------|---|----------------|
| 10 11 12 13 | HLA base profile whole- gene HLA class I (HLA-A*; HLA-B*; HLA-C*) and HLA class II (HLA-DRB1*; HLA-DQB1*; HLA-DPB1*) | Swab 2 units EDTA blood** 5 ml Extracted DNA: Volume: > 100 µl DNA concentration: minimum 20 ng/µl Swab 2 units EDTA blood** 5 ml Extracted DNA: Volume: > 100 µl DNA concentration: minimum 20 ng/µl | see findings | NGS-LR | with CE-IVD-certified reagents Optional additional profile HLA-DRB3/4/5*; HLA-DQA1*; HLA-DPA1* KL with reagents developed in-house | 5-7 |
| 14 15 | HLA base profile SSO HLA class I (HLA-A*; HLA-B*; HLA-C*) and HLA class II (HLA-DRB1*; HLA-DQB1*; HLA-DPB1*) | Swab 2 units EDTA blood** 5 ml Extracted DNA: Volume: > 100 µl DNA concentration: minimum 20 ng/µl | see findings | sso | With CE-IVD-certified reagents Optional additional profile HLA-DRB3/4/5*; HLA-DQA1*; HLA-DPA1* | 2-3 |
| 17 18 19 | HLA single locus HLA-A*; HLA-B*; HLA-C*; HLA-DRB1*; (HLA-DRB3/4/5*) HLA-DQB1*; (HLA-DQA1*); HLA-DPB1*; (HLA-DPA1*) | Swab 2 units EDTA blood** 5 ml Extracted DNA: Volume: > 100 µl DNA concentration: minimum 20 ng/µl | see findings | sso | with CE-IVD-certified reagents In the case of disease associations, there must be a declaration of consent. | 2-3 |

| ID: 6708 , Version: 004/12.2024 Valid from: 03.12.2024 Next review: 03.12.2026 |
|--|
|--|

List of Services

| Item | Test (DAkkS accredited according to DIN EN ISO 15189 in its currently valid version) | Material/quantity | Evaluation criteria | Method | Application area | TAT (in WD) |
|----------|--|--|---------------------|--------|---|----------------|
| 20 21 22 | HLA complete profile exon HLA class I (HLA-A*; HLA-B*; HLA-C*; HLA-E*) and HLA class II (HLA-DRB1*; HLA-DQB1*; HLA-DPB1*; HLA-DRB3/4/5*; HLA-DQA1*; HLA-DPA1*) MIC-A*, MIC-B*, KIR*, ABO*, RhD*, | Swab 2 units EDTA blood** 2 ml Extracted DNA: Volume: > 100 µl DNA concentration: minimum 20 ng/µl | see findings | NGS-E | HD with reagents developed in-house | 20 |
| 23 | CCR5Δ32* HLA complete profile exon + CMV HLA class I (HLA-A*; HLA-B*; HLA-C*; HLA-E*) and HLA class II (HLA-DRB1*; HLA-DQB1*; HLA-DPB1*; HLA-DRB3/4/5*; HLA-DQA1*; HLA-DPA1*) MIC-A*, MIC-B*, KIR*, ABO*, RhD*, CCR5Δ32* CMV virus antibodies (IgG) | Swab 3 units | see findings | NGS-E | HD with reagents developed in-house with commercial kit | 20 |
| 24 | Cross-matching HLA class I Cross-matching HLA class II | from the donor: EDTA-, ACD-blood, 10 ml and from the recipient: Serum***, Or whole blood 10 ml | see findings | LCT | KL Heparin blood, citrated blood and CPDA blood are also accepted. Donor blood must not be older than 48 hours. | 2 |

^{*} Molecular genetic analysis

| ID: 6708, Version: 004/12.2024 |
|--------------------------------|
|--------------------------------|

^{**} EDTA blood is preferable; alternatively, heparin blood, citrated blood or ACD/CPDA blood

^{***} Serum preferred, alternatively plasma

List of Services

4 Subsequent reporting from laboratory testing

In some circumstances, laboratory parameters can be requested later from sample material stored in the laboratory. Depending on the laboratory storage capacity and provided they are still suitable for it, the sample materials remain available for a certain time for additional requests.

For certain parameters, however, subsequent determinations should be made for a restricted time period only, due to the limited stability of the analysis. Below, you will find a table of parameters with restricted reporting periods.

| Test | Recommended max. reporting period | Remarks |
|-------------------|-----------------------------------|---|
| CMV determination | 3 weeks after sample collection | A valid CMV determination can be guaranteed within 4 weeks after sample collection. |
| KL HLA typing | Upon consultation | DNA analyses are subject to the provisions of the German Genetic Diagnostics Act. |

|--|